Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece

Size: px
Start display at page:

Download "Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece"

Transcription

1 Journal of Antimicrobial Chemotherapy (2008) 62, doi: /jac/dkn134 Advance Access publication 1 April 2008 Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece Joseph Papaparaskevas 1 *, Angeliki Pantazatou 2, Anastasia Katsandri 1,2, Dimitra P. Houhoula 1, Nicholas J. Legakis 1, Athanassios Tsakris 1 and Athina Avlamis 2 1 Department of Microbiology, Medical School, University of Athens, Athens, Greece; 2 Department of Microbiology, Laikon University Hospital, Athens, Greece Received 29 November 2007; returned 2 February 2008; revised 14 February 2008; accepted 5 March 2008 Objectives: Moxifloxacin is recommended in the empirical treatment of infections involving Gram-negative anaerobes. However, current European data regarding its activity against anaerobic pathogens are limited. In order to evaluate its potency, we comparatively studied the activity of moxifloxacin against recently isolated Gram-negative anaerobes. Methods: Four hundred and ninety-five Gram-negative anaerobic clinical isolates (296 Bacteroides fragilis group, 58 non-fragilis Bacteroides spp. and 141 Prevotella spp.) were prospectively recovered in six Greek hospitals. Moxifloxacin MICs were determined in comparison with those of penicillin, piperacillin/tazobactam, cefoxitin, imipenem, metronidazole and clindamycin. Results: Overall moxifloxacin MIC 50 and MIC 90 were 2 and 32 mg/l, respectively. Based on the current CLSI breakpoints (susceptible, 2 mg/l; resistant, 8 mg/l), almost half of the total isolates (49%) were non-susceptible to moxifloxacin (32% resistant; 17% intermediate). This was more evident among the non-fragilis Bacteroides species, where 47% of the isolates were resistant and 14% intermediate to moxifloxacin. Species variation was noticed, with the highest non-susceptible rates detected among Prevotella oralis (90%), Prevotella bivia (80%), Bacteroides thetaiotaomicron (75%), Bacteroides uniformis (70%) and Bacteroides capillosus (67%) species. Among the 19 (4%) isolates that were metronidazole non-susceptible (MIC 16 mg/l), only 4 (21%) were additionally non-susceptible to moxifloxacin. Conclusions: High resistance rates to moxifloxacin among Bacteroides and Prevotella spp. were recorded, exceeding those previously reported in Europe and contraindicating its use as monotherapy for infections involving Gram-negative anaerobes without prior microbiological confirmation. For empirical usage, moxifloxacin should be combined with metronidazole in order to cover for these pathogens. Keywords: metronidazole, susceptibility, anaerobes, epidemiology, Bacteroides spp., Prevotella spp. Introduction Although anaerobic bacteria play a significant role in polymicrobial infections, 1 not all hospital laboratories include the performance of anaerobic cultures in their routine protocols, and only selected centres perform susceptibility testing. In that respect, antimicrobial chemotherapy is mainly empirical and is based on data from multicentre studies. 1,2 Nevertheless, resistance to all antimicrobial agents with activity against anaerobes has been reported, as well as great variations in different geographical areas, 1 thus demanding more frequent periodic resistance surveillance. Intra-abdominal infections are commonly due to mixed aerobic and anaerobic bacteria requiring broad-spectrum antibiotic therapy. 2 Moxifloxacin is a relatively new methoxyquinolone with potent antimicrobial activity against both aerobic and anaerobic bacteria. 3 In that respect, it has been included in the guidelines for treatment of intra-abdominal infections. 2 However, a limited number of recent studies, mainly from the USA, indicate an increase in moxifloxacin resistant rates among Bacteroides and Prevotella spp. 4,5 Comparable recent European data are scarce and only a single study reported a shift towards increased resistance *Corresponding author. Tel: þ ; Fax: þ ; ipapapar@med.uoa.gr # The Author Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org

2 Papaparaskevas et al. The present study was undertaken to determine the comparative in vitro activities of moxifloxacin against Bacteroides and Prevotella spp. clinical isolates, in order to verify its usefulness in the empirical treatment of multibacterial infections involving Gram-negative anaerobes. Materials and methods Gram-negative anaerobic clinical isolates belonging to Bacteroides or Prevotella genus were consecutively collected during , from six general hospitals in Athens (five hospitals with adult patients and one with paediatric), with 3000 beds in total. All isolates were non-duplicate and derived from documented infections, for which patients received antimicrobial chemotherapy. The initial bacterial isolation and identification was performed in the individual laboratories. Subsequently, all isolates were collected from the Laboratory of Laikon University Hospital, where level III species identification was confirmed using the special potency disc method, grown in the presence of 20% bile (Bacteroides-Bile Esculin agar plates; Bioprepare, 16346, Gerakas, Greece), indole reaction (Bioprepare), and the biochemical profile using the ID32ANA system (biomérieux, Marcy l Étoile, France). 7 MICs of penicillin, piperacillin/tazobactam, cefoxitin, imipenem, metronidazole, clindamycin and moxifloxacin were determined by the Etest method (AB Biodisk, Solna, Sweden), according to the manufacturer s instructions. Briefly, a suspension with a turbidity equivalent to that of a 1.0 McFarland standard in brucella broth was prepared from a 48 h culture plate and spread onto brucella agar plates supplemented with 5% (v/v) horse blood, vitamin K 1 (1 mg/l) and haemin (5 mg/l). Susceptibility testing plates were incubated at 378C for 48 h in a Bactron 1.5 Anaerobic Chamber (Cheldon Manufacturing, Cornelius, OR, USA). Susceptibilities were interpreted according to the CLSI guidelines. 8 For moxifloxacin, the recent CLSI breakpoints were used (susceptible, 2 mg/l; intermediate, 4 mg/l; resistant, 8mg/L). 8 Bacteroides fragilis ATCC and Bacteroides thetaiotaomicron ATCC strains were used for quality control. 8 Throughout the study, anaerobiosis was ensured with methylene blue strips and resazurine. Results A total of 495 non-repetitive Gram-negative anaerobic bacteria, identified as Bacteroides or Prevotella spp., were isolated during the period of the study. Abdominal infections (55.3%) along with diabetic foot and other soft tissue infections (24.6%) were the most common sources of isolation; less frequent sources were respiratory tract infections (11.2%) and bacteraemias (8.9%). The dominant species was B. fragilis (n ¼ 165; 33.3%) and the majority of the isolates belonged to B. fragilis group (n ¼ 296, 59.8%), whereas 58 isolates (11.7%) were identified as non-fragilis Bacteroides spp. and 141 isolates (28.5%) were identified as Prevotella spp. MIC ranges, MIC 50 and MIC 90 values, and rates of resistant, intermediate and susceptible isolates for each antimicrobial agent among all Gram-negative bacteria, as well as B. fragilis group, Bacteroides spp. non-fragilis, Prevotella spp. and the most frequent species, are summarized in Table 1. Overall moxifloxacin MIC 50 and MIC 90 were 2 and 32 mg/l, respectively. Almost half of the total isolates (49%) were nonsusceptible to moxifloxacin (32% resistant; 17% intermediate). This was more evident among non-fragilis Bacteroides spp., where 47% of the isolates were resistant and 14% intermediate, whereas lower non-susceptible rates were observed for B. fragilis group (29% resistant; 13% intermediate) and Prevotella spp. (38% resistant; 4% intermediate). The high non-susceptible rate of the non-fragilis group should be attributed to the Bacteroides capillosus, which was the most prevalent species of this group and exhibited the highest non-susceptible rates (54% resistant; 13% intermediate). This is reported for the first time, as no other comparable data are available in the literature. Variations in the moxifloxacin resistance rates were recorded among the B. fragilis group species. Regarding the five most prevalent species (comprising 91% of the group isolates), B. thetaiotaomicron exhibited the highest non-susceptible rates (75%, all fully resistant), followed by Bacteroides uniformis (55% resistant, 15% intermediate), whereas lower non-susceptible rates were observed for Bacteroides distasonis (29% resistant, 11% intermediate), B. fragilis (16% resistant, 14% intermediate) and Bacteroides vulgatus (14% resistant, 16% intermediate). Variations were also recorded within the Prevotella spp. group, where the most prevalent species exhibited the highest resistance rates (Prevotella bivia, 71% resistant and 9% intermediate; Prevotella oralis, 62% resistant and 28% intermediate), whereas the rest of Prevotella spp. isolates exhibited an overall nonsusceptible rate of 29%. Regarding the remaining tested antimicrobials, 90% of the isolates were non-susceptible to penicillin (MIC, 1 mg/l), 34% to clindamycin (MIC, 4 mg/l), 26% to cefoxitin (MIC, 32 mg/l), 4% to metronidazole (MIC, 16 mg/l), 2% to piperacillin/tazobactam (MIC, 64 mg/l) and,1% to imipenem (MIC, 8 mg/l). Discussion Our study showed that resistance to moxifloxacin is prevalent among Gram-negative anaerobic species, and the resistance rates described herein are even higher than those reported previously. 4,5 Comparable recent data from Europe do not exist, apart from a Belgian study indicating a possible equivalent increase. 6 It should be noted that in two previous European studies for the period , 1,9 lower resistance rates to moxifloxacin were reported (16% to 19%, at a breakpoint of 8 mg/l), and only in certain Bacteroides species, an increasing trend was noted. 9 However, two recent studies from the USA, 10,11 one of which also examined the activity of moxifloxacin against Bacteroides spp. strains isolated before its introduction in clinical practice, 10 have shown increasing resistance rates over time to moxifloxacin (overall 28% to 34.5%, at a breakpoint of 8 mg/l), as well as other newer quinolones. This kind of cross-resistance may be attributed to previous heavy clinical use of fluoroquinolones, resulting possibly in mutations at the same gene target and explaining the geographical variations of resistance. 6,10 In comparison to other European countries, Greece has experienced higher quinolone consumption rates, 12 which may explain to a certain degree the findings of the present study. Given the fact, however, that phenotypic resistance to moxifloxacin is expected to emerge at a slower rate than in older fluoroquinolones, because it requires two mutations in gyra gene, 10 other mechanisms, like multidrug efflux pumps, 13 might also be responsible. 138

3 Moxifloxacin resistance among anaerobic bacteria Table 1. Activities of moxifloxacin and comparator agents against Bacteroides and Prevotella spp. clinical isolates MIC (mg/l) Susceptibility (%) a Species (no. of strains) Antimicrobial agent range MIC 50 MIC 90 R I S Total Gram-negatives (495) moxifloxacin to penicillin to piperacillin/tazobactam to cefoxitin to imipenem to , clindamycin to metronidazole to Bacteroides spp. (354) moxifloxacin to penicillin to piperacillin/tazobactam to cefoxitin to imipenem to , clindamycin to metronidazole to B. fragilis group b (296) moxifloxacin to penicillin to piperacillin/tazobactam to cefoxitin to imipenem to , clindamycin to metronidazole to B. fragilis (165) moxifloxacin to penicillin 0.25 to piperacillin/tazobactam to cefoxitin 0.5 to imipenem to , clindamycin to metronidazole B. thetaiotaomicron (42) moxifloxacin to penicillin to piperacillin/tazobactam cefoxitin 2 to imipenem clindamycin to metronidazole B. uniformis (27) moxifloxacin 0.25 to penicillin 0.5 to piperacillin/tazobactam cefoxitin imipenem clindamycin to metronidazole B. distasonis (20) moxifloxacin 0.5 to penicillin 16 to piperacillin/tazobactam cefoxitin 1 to imipenem clindamycin to metronidazole B. vulgatus (15) moxifloxacin to penicillin 0.5 to piperacillin/tazobactam to cefoxitin 0.25 to Continued 139

4 Papaparaskevas et al. Table 1. Continued MIC (mg/l) Susceptibility (%) a Species (no. of strains) Antimicrobial agent range MIC 50 MIC 90 R I S imipenem to clindamycin to metronidazole to Bacteroides spp. non-fragilis c (58) moxifloxacin to penicillin to piperacillin/tazobactam to cefoxitin imipenem clindamycin to metronidazole B. capillosus (44) moxifloxacin to penicillin 1 to piperacillin/tazobactam to cefoxitin imipenem clindamycin to metronidazole Prevotella spp. d (141) moxifloxacin to penicillin to piperacillin/tazobactam cefoxitin imipenem clindamycin to metronidazole to P. bivia (35) moxifloxacin 0.5 to penicillin piperacillin/tazobactam cefoxitin imipenem clindamycin to metronidazole to P. oralis (29) moxifloxacin 0.5 to penicillin to piperacillin/tazobactam cefoxitin imipenem clindamycin to metronidazole to a R, resistant; I, intermediate; S, susceptible. b Includes: B. fragilis (165), B. thetaiotaomicron (42), B. uniformis (27), B. distasonis (20), B. vulgatus (15), B. ovatus (9), B. merdae (7), B. caccae (6), B. eggerthii (5). c Includes: B. capillosus (44), B. ureolyticus (14). d Includes: P. bivia (35), P. oralis (29), P. buccae (12), P. disiens (12), P. loescheii (11), P. buccalis (10), P. indermedia (10), P. denticola (9), P. melaninogenica (9), P. ruminicola (4). The variation in the resistance of various species reported herein seems to differ from other studies, where isolates identified as B. vulgatus, 1,10,11 Bacteroides ovatus 1,6,10 or B. distasonis 10 were among the most resistant species, indicating variations not only among species but also between different geographic regions, as has been suggested previously. 1,10,11 In addition, although previous studies have reported even higher moxifloxacin resistance among certain Bacteroides species (such as B. vulgatus), 1,11 our study indicated that this resistance seems to affect many species belonging not only to Bacteroides but also to Prevotella genus. A high intermediate rate (MIC ¼ 4 mg/l) was recorded in many species, an observation that needs continuous active surveillance. Resistance rates to other antimicrobials with activity against anaerobes, such as penicillin, cefoxitin, piperacillin/tazobactam, clindamycin, and imipenem, reported here were similar to those from the last Greek study 14 and comparable to previously reported multicentre European data. 1 In addition, metronidazole resistance 140

5 Moxifloxacin resistance among anaerobic bacteria rates were equally low (overall 3% resistant and 1% intermediate), although a shift towards isolation of metronidazole-resistant Bacteroides spp. was detected. In the previous Greek study, 14 metronidazole resistance was 3% and was almost exclusively detected among isolates identified as Prevotella spp., whereas in the present study, as many as 44% of the metronidazole-resistant isolates were Bacteroides spp. A total of 19 isolates were metronidazole non-susceptible (14 isolates resistant, MIC 32 mg/l; 5 isolates intermediate, MIC ¼ 16 mg/l), of which only 4 (21%) were additionally moxifloxacin resistant (MIC 8 mg/l). In that respect, moxifloxacin, although exhibiting high resistance rates, seems to be effective against isolates conferring resistance to metronidazole, thus making its combination with metronidazole still an acceptable solution for the anaerobic pathogens of intra-abdominal infections, according to guidelines. 3 In conclusion, this multicentre study in Greece showed that moxifloxacin exhibited high intermediate and fully resistant rates against Bacteroides and Prevotella species, the highest reported so far in Europe, thus making full species identification of all anaerobes isolated from clinical specimens mandatory, as well as performance of susceptibility testing, in order to justify its administration as monotherapy. For empirical usage, moxifloxacin should be combined with metronidazole in order to cover for these pathogens. Acknowledgements We are thankful to the following members of the Hellenic Study Group for Gram-Negative Anaerobic Bacteria for contributing isolates to this study: Dr E. Papafrangas and Dr M. Kanellopoulou (Sismanoglion General Hospital), Dr C. Koutsia-Karouzou and Dr D. Kairis (Asklepeion General Hospital), Dr C. Trikka-Graphakos (Thriassion General Hospital), Dr H. Malamou-Ladas and Dr G. Ganteris (G. Gennimatas General Hospital), and Dr A. Vogiatzi (Penteli s Children Hospital). Funding This study was co-funded by the European Social Fund and National Resources (grants EPEAEK II Pythagoras II and Kapodistrias). Transparency declarations None to declare. References 1. Hedberg M, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003; 9: Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: Ackermann G, Schaumann R, Pless B et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000; 19: Citron DM, Goldstein EJC, Merriam CV et al. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007; 45: Goldstein EJC, Citron DM, Warren YA et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: Wybo I, Pierard D, Verschraegen I et al. Third Belgian multicenter survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2007; 59: Jousimies-Somer HR, Summanen P, Citron DM et al. Wadsworth KTL Anaerobic Bacteriology Manual, 6th edn. Belmont, CA: Star Publishing Company, 2002; Clinical and Laboratory Standards Institute. Methods for Antimicrobial Testing of Anaerobic Bacteria Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, Betriu C, Rodríguez-Avial I, Gomez M et al. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period ( ). Diagn Microbiol Infect Dis 2005; 53: Golan Y, McDermott LA, Jacobus NV et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 2003; 52: Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to Antimicrob Agents Chemother 2007; 51: Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58: Miyamae S, Ueda O, Yoshimura F et al. A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother 2001; 45: Katsandri A, Avlamis A, Pantazatou A et al. In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains. Diagn Microbiol Infect Dis 2006; 55:

Multicenter Study of Antimicrobial Susceptibility of Anaerobic Bacteria in Korea in 2012

Multicenter Study of Antimicrobial Susceptibility of Anaerobic Bacteria in Korea in 2012 Original Article Clinical Microbiology Ann Lab Med 2015;35:479-486 http://dx.doi.org/10.3343/alm.2015.35.5.479 ISSN 2234-3806 eissn 2234-3814 Multicenter Study of Antimicrobial Susceptibility of Anaerobic

More information

Antimicrobial Susceptibility of Clinical Isolates of Bacteroides fragilis Group Organisms Recovered from 2009 to 2012 in a Korean Hospital

Antimicrobial Susceptibility of Clinical Isolates of Bacteroides fragilis Group Organisms Recovered from 2009 to 2012 in a Korean Hospital Original Article Clinical Microbiology Ann Lab Med 2015;35:94-98 http://dx.doi.org/10.3343/alm.2015.35.1.94 ISSN 2234-3806 eissn 2234-3814 Antimicrobial Susceptibility of Clinical Isolates of Bacteroides

More information

on February 12, 2018 by guest

on February 12, 2018 by guest AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of

More information

SESSION XVI NEW ANTIBIOTICS

SESSION XVI NEW ANTIBIOTICS SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:

More information

Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience

Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience ORIGINAL ARTICLE BACTERIOLOGY Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience E. Nagy 1, E. Urbán 1 and Carl Erik Nord on behalf of the ESCMID Study

More information

Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data ( )

Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data ( ) SUPPLEMENT ARTICLE Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data (2005 2007) David R. Snydman, 1,2 Nilda V. Jacobus, 1 Laura A. McDermott, 1 Yoav Golan,

More information

ANTI-ANAEROBIC ACTIVITIES OF SULOPENEM COMPARED TO SIX OTHER. Departments of Pathology, Hershey Medical Center, Hershey, PA 17033

ANTI-ANAEROBIC ACTIVITIES OF SULOPENEM COMPARED TO SIX OTHER. Departments of Pathology, Hershey Medical Center, Hershey, PA 17033 AAC Accepts, published online ahead of print on 17 February 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01557-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Reiner Schaumann, 1 Ellie J. C. Goldstein, 2 Jochen Forberg 3 and Arne C. Rodloff 1

Reiner Schaumann, 1 Ellie J. C. Goldstein, 2 Jochen Forberg 3 and Arne C. Rodloff 1 Journal of Medical Microbiology (2005), 54, 4 53 DOI 10.10/jmm.0.454-0 Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/ pharmacodynamic model employing

More information

Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria

Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria Journal of Antimicrobial Chemotherapy (2007) 59, 132 139 doi:10.1093/jac/dkl458 Advance Access publication 9 November 2006 Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria

More information

Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy

Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S2, ii29 ii36 DOI: 10.1093/jac/dkh201 Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem

More information

Marc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium

Marc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

More information

ORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA

ORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton

More information

Multicenter Study of In Vitro Susceptibility of the Bacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996

Multicenter Study of In Vitro Susceptibility of the Bacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1999, p. 2417 2422 Vol. 43, No. 10 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Multicenter Study of In Vitro

More information

Should we test Clostridium difficile for antimicrobial resistance? by author

Should we test Clostridium difficile for antimicrobial resistance? by author Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first

More information

Antimicrobial Resistance in Human Oral and Intestinal Anaerobic Microfloras

Antimicrobial Resistance in Human Oral and Intestinal Anaerobic Microfloras ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1993, p. 1665-1669 Vol. 37, No. 8 0066-4804/93/081665-05$02.00/0 Copyright X 1993, American Society for Microbiology Antimicrobial Resistance in Human Oral and

More information

Anaerobic bacteria in 118 patients with deepspace head and neck infections from the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria

Anaerobic bacteria in 118 patients with deepspace head and neck infections from the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria Journal of Medical Microbiology (2006), 55, 1285 1289 DOI 10.1099/jmm.0.46512-0 Anaerobic bacteria in 118 patients with deepspace head and neck infections from the University Hospital of Maxillofacial

More information

Antimicrobial susceptibility of Neisseria gonorrhoeae in Greece: data for the years

Antimicrobial susceptibility of Neisseria gonorrhoeae in Greece: data for the years Journal of Antimicrobial Chemotherapy (2006) 57, 775 779 doi:10.1093/jac/dkl040 Advance Access publication 21 February 2006 Antimicrobial susceptibility of Neisseria gonorrhoeae in Greece: data for the

More information

Susceptibility Testing of Anaerobic Bacteria: Evaluation of the Redesigned (Version 96) biomérieux ATB ANA Device

Susceptibility Testing of Anaerobic Bacteria: Evaluation of the Redesigned (Version 96) biomérieux ATB ANA Device JOURNAL OF CLINICAL MICROBIOLOGY, June 1999, p. 1824 1828 Vol. 37, No. 6 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Susceptibility Testing of Anaerobic

More information

.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005

.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005 .'URRENT THERAPEUTIC RESEA VOLUME 66, NUMBER 3, MAY/JuNE 2005 Efficacy of Moxifloxacin Monotherapy Versus Gatifloxacin Monotherapy, Piperacillin- Tazobactam Combination Therapy, and Clindamycin Plus Gentamicin

More information

Anaerobe bakterier og resistens. Ulrik Stenz Justesen Klinisk Mikrobiologisk Afdeling Odense Universitetshospital Odense, Denmark

Anaerobe bakterier og resistens. Ulrik Stenz Justesen Klinisk Mikrobiologisk Afdeling Odense Universitetshospital Odense, Denmark Anaerobe bakterier og resistens Ulrik Stenz Justesen Klinisk Mikrobiologisk Afdeling Odense Universitetshospital Odense, Denmark Programme anaerobic bacteria Carbapenem and metronidazole resistance New

More information

Received: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008

Received: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008 J Microbiol Immunol Infect. 29;42:317-323 In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center

More information

Antimicrobial Susceptibility of Clinically Relevant Gram-Positive Anaerobic Cocci Collected over a Three-Year Period in the Netherlands

Antimicrobial Susceptibility of Clinically Relevant Gram-Positive Anaerobic Cocci Collected over a Three-Year Period in the Netherlands ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2011, p. 1199 1203 Vol. 55, No. 3 0066-4804/11/$12.00 doi:10.1128/aac.01771-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Antimicrobial

More information

AAC Revised. Activity of a Novel Cyclic Lipopeptide, CB-183,315 Against Resistant Clostridium difficile

AAC Revised. Activity of a Novel Cyclic Lipopeptide, CB-183,315 Against Resistant Clostridium difficile AAC Accepts, published online ahead of print on 5 March 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.06257-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 AAC06257-11

More information

Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents

Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents Journal of Antimicrobial Chemotherapy (2004) 53, 1039 1044 DOI: 10.1093/jac/dkh248 Advance Access publication 5 May 2004 Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic

More information

SUPPLEMENT ARTICLE BIPHASIC MIXED INFECTION

SUPPLEMENT ARTICLE BIPHASIC MIXED INFECTION SUPPLEMENT ARTICLE Intra-Abdominal Anaerobic Infections: Bacteriology and Therapeutic Potential of Newer Antimicrobial Carbapenem, Fluoroquinolone, and Desfluoroquinolone Therapeutic Agents Ellie J. C.

More information

In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain

In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain J Antimicrob Chemother 2015; 70: 2311 2315 doi:10.1093/jac/dkv092 Advance Access publication 15 April 2015 In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium

More information

ACCEPTED. Anaerobe Reference Laboratory, Department of Bacterial and Inflammatory Diseases, National

ACCEPTED. Anaerobe Reference Laboratory, Department of Bacterial and Inflammatory Diseases, National AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic

More information

Patterns of Susceptibility to Fluoroquinolones Among Anaerobic Bacterial Isolates in the United States

Patterns of Susceptibility to Fluoroquinolones Among Anaerobic Bacterial Isolates in the United States S377 Patterns of Susceptibility to Fluoroquinolones Among Anaerobic Bacterial Isolates in the United States Ellie J. C. Goldstein From R. M. Alden Research Laboratory, Santa Monica Hospital Medical Center,

More information

Ciprofloxacin, Enoxacin, and Ofloxacin against Aerobic and

Ciprofloxacin, Enoxacin, and Ofloxacin against Aerobic and ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1988, p. 1143-1148 Vol., No. 8 0066-4804/88/081143-06$00/0 Copyright 1988, American Society for Microbiology Comparative Activities of, Amoxicillin-Clavulanic

More information

Annual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)

Annual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml) Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood

More information

Chapter Anaerobic infections (individual fields): intraperitoneal infections (acute peritonitis, hepatobiliary infections, etc.

Chapter Anaerobic infections (individual fields): intraperitoneal infections (acute peritonitis, hepatobiliary infections, etc. J Infect Chemother (2011) 17 (Suppl 1):84 91 DOI 10.1007/s10156-010-0146-5 GUIDELINES Chapter 2-5-4. Anaerobic infections (individual fields): intraperitoneal infections (acute peritonitis, hepatobiliary

More information

Effect of dalbavancin on the normal intestinal microflora

Effect of dalbavancin on the normal intestinal microflora Journal of Antimicrobial Chemotherapy (00), 1 doi:10.109/jac/dkl1 Advance Access publication 1 July 00 Effect of dalbavancin on the normal intestinal microflora Carl Erik Nord*, Gundars Rasmanis and Elisabeth

More information

Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017

Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017 Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017

More information

Tel: Fax:

Tel: Fax: CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.

More information

Int.J.Curr.Microbiol.App.Sci (2017) 6(3):

Int.J.Curr.Microbiol.App.Sci (2017) 6(3): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104

More information

Mili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh

Mili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original

More information

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are

More information

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production

More information

APPENDIX III - DOUBLE DISK TEST FOR ESBL

APPENDIX III - DOUBLE DISK TEST FOR ESBL Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January

More information

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative Journal of Antimicrobial Chemotherapy (2008) 62, 116 121 doi:10.1093/jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates:

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

Antibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?

Antibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs? Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration

More information

International Journal of Antimicrobial Agents 28 (2006)

International Journal of Antimicrobial Agents 28 (2006) International Journal of Antimicrobial Agents 28 (2006) 532 536 Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum -lactamase-producing Escherichia coli in

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Prevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India

Prevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India International Journal of Current Microbiology and Applied Sciences ISSN: 319-77 Volume Number (17) pp. 57-3 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/1.5/ijcmas.17..31

More information

R. M. Alden Research Laboratory, Santa Monica, California 90404, 1 and David Geffen School of Medicine at UCLA, Los Angeles, California

R. M. Alden Research Laboratory, Santa Monica, California 90404, 1 and David Geffen School of Medicine at UCLA, Los Angeles, California ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2006, p. 2875 2879 Vol. 50, No. 8 0066-4804/06/$08.00 0 doi:10.1128/aac.00286-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. In Vitro

More information

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase

More information

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain

More information

Piperacillin-Tazobactam, and Cefoxitin

Piperacillin-Tazobactam, and Cefoxitin ANTiMICROBLAL AGENTS AND CHEMOTHERAPY, Aug. 1993, p. 1649-1654 0066-4804/93/081649-06$00/0 Copyright 1993, American Society for Microbiology Vol. 37, No. 8 Susceptibilities of 428 Gram-Positive and -Negative

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research  ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Antibiotic Susceptibility Pattern of Pseudomonas Aeruginosa Isolated From Various Clinical

More information

Received 10 November 2006/Returned for modification 9 January 2007/Accepted 17 July 2007

Received 10 November 2006/Returned for modification 9 January 2007/Accepted 17 July 2007 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2007, p. 3726 3730 Vol. 51, No. 10 0066-4804/07/$08.00 0 doi:10.1128/aac.01406-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparative

More information

Principles and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013

Principles and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013 Principles and Practice of Antimicrobial Susceptibility Testing Microbiology Technical Workshop 25 th September 2013 Scope History Why Perform Antimicrobial Susceptibility Testing? How to Perform an Antimicrobial

More information

Activity of Linezolid Tested Against Uncommonly Isolated Gram-positive ACCEPTED

Activity of Linezolid Tested Against Uncommonly Isolated Gram-positive ACCEPTED AAC Accepts, published online ahead of print on 8 January 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01496-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Effect of Lactobacillus F19 on the emergence of antibioticresistant microorganisms in the intestinal microflora

Effect of Lactobacillus F19 on the emergence of antibioticresistant microorganisms in the intestinal microflora Journal of Antimicrobial Chemotherapy (2004) 54, 791 797 DOI: 10.1093/jac/dkh406 Advance Access publication 25 August 2004 Effect of Lactobacillus F19 on the emergence of antibioticresistant microorganisms

More information

Fluoroquinolones and Anaerobes

Fluoroquinolones and Anaerobes REVIEWS OF ANTI-INFECTIVE AGENTS Louis D. Saravolatz, Section Editor INVITED ARTICLE Fluoroquinolones and Anaerobes Gary E. Stein 1,2 and Ellie J. C. Goldstein 3,4 Departments of 1 Medicine and 2 Pharmacology,

More information

Epidemiology and Antimicrobial Susceptibility of Anaerobic Bloodstream Infections: A 10 Years Study

Epidemiology and Antimicrobial Susceptibility of Anaerobic Bloodstream Infections: A 10 Years Study JMID/ 2018; 8 (4):135-139 Journal of Microbiology and Infectious Diseases doi: 10.5799/xxxxx RESEARCH ARTICLE Epidemiology and Antimicrobial Susceptibility of Anaerobic Bloodstream Infections: A 10 Years

More information

Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing

Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate

More information

ORIGINAL ARTICLE. influenzae and Moraxella catarrhalis to antimicrobial agents used to treat respiratory tract infections.

ORIGINAL ARTICLE. influenzae and Moraxella catarrhalis to antimicrobial agents used to treat respiratory tract infections. ORIGINAL ARTICLE Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil, 1997 98 I. A. Critchley 1, C. Thornsberry

More information

Ecological impact of the des-f(6)-quinolone, BMS , on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M.

Ecological impact of the des-f(6)-quinolone, BMS , on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M. ORIGINAL ARTICLE Ecological impact of the des-f(6)-quinolone, BMS-284756, on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M. Grasela 2 1 Department of Microbiology, Pathology and

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.

More information

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062

More information

Original Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e.

Original Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e. Iranian Journal of Pharmaceutical Research (22), (2): 559-563 Received: January 2 Accepted: June 2 Copyright 22 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services

More information

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.** Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

Present Status of Therapy for Anaerobic Infections

Present Status of Therapy for Anaerobic Infections 89 Present Status of Therapy for Anaerobic Infections Sydney M. Finegold and Hannah M. Wexler From the Medical and Research Services, Veterans Affairs Medical Center West Los Angeles, and the Department

More information

PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996

PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996 PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY

More information

SAMPLE. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

SAMPLE. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals VET01 5th Edition Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals This standard covers the current recommended methods for disk diffusion

More information

Isolation and Antibiogram of Enterococci from Patients with Urinary Tract Infection in a Tertiary Care Hospital

Isolation and Antibiogram of Enterococci from Patients with Urinary Tract Infection in a Tertiary Care Hospital International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 8 (2016) pp. 658-662 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.508.074

More information

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.

More information

Background and Plan of Analysis

Background and Plan of Analysis ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Anaerobic Bacteria in Intra-Abdominal Infections and Bacteremia Maria Hedberg, Umeå University, Umeå, Sweden Anaerobic Bacteria: Next Generation Technology Meets Anaerobic Diagnostics ESCMID Postgraduate

More information

levofloxacin (LVFX) LVFX LVFX LVFX Key words: Levofloxacin Escherichia coli LVFX levofloxacin (LVFX) Vol. 18 No

levofloxacin (LVFX) LVFX LVFX LVFX Key words: Levofloxacin Escherichia coli LVFX levofloxacin (LVFX) Vol. 18 No 2008 221 20 3 14 20 8 1 2001 1 2005 12 5 levofloxacin (LVFX) 5 811 125 27 LVFX (MIC: 4 mg/ml) LVFX LVFX Key words: Levofloxacin Escherichia coli 1) 2 5) 6) ( 203 0036) 2 1 2 TEL: 042 338 5111 2254 FAX:

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

EUCAST-and CLSI potency NEO-SENSITABS

EUCAST-and CLSI potency NEO-SENSITABS EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme

More information

Original ABSTRACT RESUMEN. Estela Cordero-Laurent César Rodríguez Evelyn Rodríguez-Cavallini María del Mar Gamboa- Coronado Carlos Quesada-Gómez

Original ABSTRACT RESUMEN. Estela Cordero-Laurent César Rodríguez Evelyn Rodríguez-Cavallini María del Mar Gamboa- Coronado Carlos Quesada-Gómez Original Estela Cordero-Laurent César Rodríguez Evelyn Rodríguez-Cavallini María del Mar Gamboa- Coronado Carlos Quesada-Gómez Resistance of Bacteroides isolates recovered among clinical samples from a

More information

Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli

Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli CRL Campylobacter Workshop The 7th -8th of Oct. 2008 National Veterinary Institute Uppsala, Sweden Legislation The Commission has

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections are they applicable today?

Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections are they applicable today? REVIEW 10.1111/j.1469-0691.2008.02123.x Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections are they applicable today? M. Caínzos Hospital Clínico Universitario,

More information

against Clinical Isolates of Gram-Positive Bacteria

against Clinical Isolates of Gram-Positive Bacteria ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,

More information

Case Report Multidrug-Resistant Bacteroides fragilis Bacteremia in a US Resident: An Emerging Challenge

Case Report Multidrug-Resistant Bacteroides fragilis Bacteremia in a US Resident: An Emerging Challenge Case Reports in Infectious Diseases Volume 2016, Article ID 3607125, 4 pages http://dx.doi.org/10.1155/2016/3607125 Case Report Multidrug-Resistant Bacteroides fragilis Bacteremia in a US Resident: An

More information

Comparison of Antibiotic Resistance and Sensitivity with Reference to Ages of Elders

Comparison of Antibiotic Resistance and Sensitivity with Reference to Ages of Elders Daffodil International University Institutional Repository DIU Journal of Science and Technology Volume 10, Issue 1-2, July 2015 2016-06-16 Comparison of Antibiotic Resistance and Sensitivity with Reference

More information

and Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA

and Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA Journal of Antimicrobial Chemotherapy (2004) 54, Suppl. S1, i7 i15 DOI: 10.1093/jac/dkh313 JAC Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

Methicillin resistant Staphylococcus aureus : a multicentre study

Methicillin resistant Staphylococcus aureus : a multicentre study Methicillin resistant Staphylococcus aureus : a multicentre study S. Hafiz ( Mid-East Medical Center,Karachi. ) A. N. Hafiz ( Mid-East Medical Center, Karachi. ) L. Ali ( City Medical Laboratory, Peshawer,

More information

Available online at ISSN No:

Available online at  ISSN No: Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other

More information

A Norazah, M D*, V K E Lim, FRCPath**, MY Rohani, MPath*, A G M Kamel, MD**,

A Norazah, M D*, V K E Lim, FRCPath**, MY Rohani, MPath*, A G M Kamel, MD**, I ORIGINAL ARTICLE In-Vitro Activity of Quinupristin/ Dalfopristin, Levofloxacin and Moxifloxacin Against Fusidic Acid and Rifampicin-Resistant Strains of Methicillin Resistant Staphylococcus Aureus (MRSA)

More information

Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland

Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Version 1.0 23 December 2011 General enquiries and contact details This is the first version (1.0) of the Protocol

More information

In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in in Sweden

In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in in Sweden ORIGINAL ARTICLE BACTERIOLOGY In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993 2007 in Sweden T. Norén 1,2, I. Alriksson 2,T.Åkerlund 3, L. G. Burman

More information

Michael Hombach*, Guido V. Bloemberg and Erik C. Böttger

Michael Hombach*, Guido V. Bloemberg and Erik C. Böttger J Antimicrob Chemother 2012; 67: 622 632 doi:10.1093/jac/dkr524 Advance Access publication 13 December 2011 Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011

More information

An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage

An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",

More information

Key words: Campylobacter, diarrhea, MIC, drug resistance, erythromycin

Key words: Campylobacter, diarrhea, MIC, drug resistance, erythromycin Key words: Campylobacter, diarrhea, MIC, drug resistance, erythromycin Table 1 Detection rate of Campylobacter from stool samples taken from sporadic diarrheic patients Table 2 Detection rates of Campylobacter

More information

Presence of extended spectrum β-lactamase producing Escherichia coli in

Presence of extended spectrum β-lactamase producing Escherichia coli in 1 2 Presence of extended spectrum β-lactamase producing Escherichia coli in wild geese 3 4 5 A. Garmyn* 1, F. Haesebrouck 1, T. Hellebuyck 1, A. Smet 1, F. Pasmans 1, P. Butaye 2, A. Martel 1 6 7 8 9 10

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.HNMC.24 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important

More information